News

PMLive23hOpinion
DE&I – don’t throw the baby out with the bathwater
Now more than ever we need to remain focused on the real goals of DE&I – and whether we call it that or not, we surely must ...
PMLive23h
Biogen’s Skyclarys granted MHRA approval for rare movement disorder Friedreich’s ataxia
Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the ...
PMLive23h
Roche’s Genentech enters $765m autoimmune disease partnership with Repertoire
Roche’s Genentech unit and Repertoire Immune Medicines have entered into a partnership worth $765m to discover and develop T ...
PMLive23h
Why Pharma’s Digital PI Compliance Problem Needs a Cross-Functional Fix
In many pharma teams, the responsibility for keeping prescribing information (PI) up to date online falls into a grey area. > ...
PMLive23h
Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer
Gilead Sciences has shared positive top-line results from a late-stage study evaluating its antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) with Merck & Co’s anti-PD-1 therapy ...